Table 2 Characteristics associated with research discussion

 Gender

n

%

OR

95 % CI

p-value

OR_adj^a

95 % CI

p-value

  Male

9,348

28.9

(ref)

(ref)

  Female

11,008

30.9

1.05

1.01 – 1.08

0.01

0.85

0.80 – 0.89

< 0.001

 Age group

  16 – 25

98

38.1

1.51

1.16 – 1.96

0.002

1.41

0.96 – 2.07

0.08

  26 – 35

317

35.6

1.27

1.10 – 1.46

0.001

1.14

0.97 – 1.34

0.11

  36 – 50

2,249

37.0

1.32

1.24 – 1.40

< 0.001

1.15

1.05 – 1.27

0.004

  51 – 65

7,267

36.3

1.27

1.22 – 1.32

< 0.001

1.18

1.11 – 1.25

< 0.001

  66 – 75

6,802

30.9

(ref)

(ref)

  76+

2,891

19.3

0.54

0.52 – 0.57

< 0.001

0.58

0.54 – 0.62

< 0.001

 Ethnicity

  White

18,662

30.1

(ref)

(ref)

  Mixed

132

41.8

1.72

1.37 – 2.17

< 0.001

1.29

0.97 – 1.72

0.08

  Asian/Asian British

430

37.2

1.54

1.36 – 1.74

< 0.001

1.11

0.93 – 1.33

0.26

  Black/Black British

361

40.4

1.71

1.48 – 1.96

< 0.001

1.09

0.91 – 1.30

0.35

  Other

107

38.2

1.53

1.19 – 1.96

0.001

0.97

0.70 – 1.34

0.85

 Long-standing conditions ^b

  None

12,752

32.7

  Deafness/hearing impairment

1,642

24.0

0.70

0.66 – 0.74

< 0.001

0.93

0.87 – 1.00

0.05

  Blindness/partially sighted

347

23.2

0.69

0.61 – 0.78

< 0.001

0.92

0.81 – 1.05

0.20

  Physical condition

2,483

27.9

0.86

0.81 – 0.90

< 0.001

0.92

0.87 – 0.97

0.003

  Learning disability

82

29.3

1.04

0.80 – 1.35

0.78

0.88

0.63 – 1.22

0.43

  Mental health condition

355

26.9

0.85

0.75 – 0.96

0.01

0.79

0.69 – 0.91

0.001

  Long-standing illness ^c

2,269

26.1

0.78

0.74 – 0.82

< 0.001

0.88

0.83 – 0.94

< 0.001

 Tumour group

n

%

OR

95 % CI

p-value

OR_adj^a

95 % CI

p-value

  Brain/CNS

255

35.4

1.02

0.88 – 1.20

0.77

0.69

0.53 – 0.88

0.004

  Breast

4,870

35.9

(ref)

(ref)

  Colorectal / Lower GI

2,670

30.9

0.81

0.77 – 0.86

< 0.001

0.91

0.81 – 1.02

0.12

  Gynaecological

1,016

26.9

0.67

0.62 – 0.73

< 0.001

0.64

0.55 – 0.75

< 0.001

  Haematological

3,842

33.9

0.94

0.90 – 0.99

0.03

0.85

0.72 – 1.01

0.06

  Head and Neck

659

27.6

0.71

0.64 – 0.78

< 0.001

0.59

0.47 – 0.73

< 0.001

  Lung

1,443

29.5

0.77

0.72 – 0.83

< 0.001

0.71

0.59 – 0.85

< 0.001

  Other

833

31.1

0.82

0.75 – 0.90

< 0.001

0.68

0.59 – 0.79

< 0.001

  Prostate

1,785

32.9

0.88

0.83 – 0.95

< 0.001

0.90

0.76 – 1.07

0.24

  Sarcoma

229

32.2

0.88

0.75 – 1.04

0.13

0.62

0.46 – 0.84

0.002

  Skin

316

17.7

0.38

0.34 – 0.43

< 0.001

0.35

0.25 – 0.47

< 0.001

  Upper GI

1,390

33.2

0.91

0.84 – 0.98

0.01

0.83

0.71 – 0.97

0.02

  Urological

1,048

15.4

0.33

0.30 – 0.35

< 0.001

0.33

0.28 – 0.39

< 0.001

 Time since 1 ^st treatment

  < 1 year

12,233

28.6

(ref)

(ref)

  1–5 years

5,721

35.4

1.41

1.35 – 1.46

< 0.001

1.44

1.34 – 1.55

< 0.001

  > 5 years

1,781

32.3

1.23

1.15 – 1.30

< 0.001

1.30

1.19 – 1.42

< 0.001

 Trust type

n

%

OR

95 % CI

p-value

OR_adj^a

95 % CI

p-value

  Small acute

1,384

24.5

0.99

0.92 – 1.06

0.71

1.01

0.88 – 1.18

0.85

  Medium acute

3,931

26.2

1.07

1.02 – 1.12

0.01

1.08

0.95 – 1.23

0.20

  Large acute

5,847

24.9

(ref)

(ref)

  Specialist

1,606

48.4

2.95

2.73 – 3.18

< 0.001

2.52

1.73 – 3.66

< 0.001

  Teaching

7,588

39.0

1.99

1.91 – 2.07

< 0.001

1.97

1.71 – 2.27

< 0.001

 Foundation status

  No

8,581

29.3

(ref)

(ref)

  Yes

11,775

31.2

1.10

1.07 – 1.14

< 0.001

0.97

0.88 – 1.08

0.60

 Location

  Outside London

16,576

28.7

  London

3,780

40.9

1.76

1.68 – 1.84

< 0.001

1.25

1.07 – 1.46

0.01